Reduction in Physician Reimbursement and Use of Hormone Therapy in Prostate Cancer
TLDR
The 2003 Medicare Modernization Act reduced reimbursements for AST by 64% between 2004 and 2005, but the effect of this large reduction on use of AST in prostate cancer is unknown.Abstract:
Background
Use of androgen suppression therapy (AST) in prostate cancer increased more than threefold from 1991 to 1999. The 2003 Medicare Modernization Act reduced reimbursements for AST by 64% between 2004 and 2005, but the effect of this large reduction on use of AST is unknown.read more
Citations
More filters
Journal ArticleDOI
Effect of Financial Relationships on the Behaviors of Health Care Professionals: A Review of the Evidence:
TL;DR: In this paper, the authors identify and synthesize peer-reviewed data addressing whether financial incentives are causally related to patient outcomes and health care costs, and show that such financial conflicts of interests can, and sometimes do, impact physicians' clinical decisions.
Journal ArticleDOI
Secondary Data Analysis of Large Data Sets in Urology: Successes and Errors to Avoid
TL;DR: Investigators and the urological community need to strive to use secondary data analysis of large data sets appropriately to produce high quality studies that hopefully lead to improved patient outcomes.
Journal ArticleDOI
Mp4-20 contemporary incidence and mortality rates of neuroendocrine prostate cancer
TL;DR: In this article, the authors examined changes in age-adjusted incidence (AAIR), mortality rates (MR) and 5-year cancer-specific survival (CSS) for 378 patients diagnosed with NEPC between 1992 and 2011.
Journal ArticleDOI
Medical Oncologists' Perceptions of Financial Incentives in Cancer Care
TL;DR: A substantial proportion of oncologists who are not paid a fixed salary report that their incomes increase when they administer chemotherapy and growth factors, and further research is needed to understand the impact of these financial incentives on both the quality and cost of care.
Journal ArticleDOI
A Checklist for Ascertaining Study Cohorts in Oncology Health Services Research Using Secondary Data: Report of the ISPOR Oncology Good Outcomes Research Practices Working Group
Kathy L. Schulman,Karina Berenson,Y.C.T. Shih,Kathleen A. Foley,Arijit Ganguli,Jonas A. De Souza,Nicholas A. Yaghmour,Alex Shteynshlyuger +7 more
TL;DR: A checklist focused on issues specific to selection of a sample of oncology patients using a secondary data source that can assist decision makers and reviewers in evaluating the quality of studies using secondary data.
References
More filters
Journal ArticleDOI
A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation☆
TL;DR: The method of classifying comorbidity provides a simple, readily applicable and valid method of estimating risk of death fromComorbid disease for use in longitudinal studies and further work in larger populations is still required to refine the approach.
Journal Article
Uncertainty and the Welfare Economics of Medical Care
TL;DR: In this article, the authors focus on the way in which the operation of the medical-care industry and the efficacy with which it satisfies the needs of society differ from a norm, and the most obvious distinguishing characteristics of an individual's demand for medical services is that it is not steady in origin as, for example, for food or clothing but is irregular and unpredictable.
Journal ArticleDOI
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.
Michel Bolla,Laurence Collette,Leo E.C.M. Blank,Padraig Warde,Jean Bernard Dubois,René-Olivier Mirimanoff,Guy Storme,Jacques Bernier,Abraham Kuten,Cora N. Sternberg,J Mattelaer,José Lopez Torecilla,J Rafael Pfeffer,Carmel Lino Cutajar,A Zurlo,Marianne Pierart +15 more
TL;DR: Immediate androgen suppression with an LHRH analogue given during and for 3 years after external irradiation improves disease-free and overall survival of patients with locally advanced prostate cancer.
Journal ArticleDOI
Development of a comorbidity index using physician claims data.
TL;DR: A comorbidity index that incorporates the diagnostic and procedure data contained in Medicare physician (Part B) claims and demonstrates the utility of a disease-specific index using an alternative method of construction employing study-specific weights.
PHARMACOEPIDEMIOLOGY REPORT Development of a comorbidity index using physician claims data
TL;DR: This article developed a comorbidity index that incorporates the diagnostic and procedure data contained in Medicare physician (Part B) claims, which significantly contributes to models of 2-year noncancer mortality and treatment received in both patient cohorts.